
PRESS RELEASE

STOCKHOLM, SEPTEMBER 23, 2021

National Cancer Centre Singapore selects RayStation for new proton center

RaySearch Laboratories AB (publ) announces that the National Cancer Centre Singapore (NCCS) has placed an order for RayStation® as the treatment planning system for its new proton therapy center currently under construction and scheduled for completion by 2022.*

NCCS provides a holistic, multi-disciplinary approach to cancer treatment and patient care, and sees close to 65 percent of Singapore's public sector oncology cases.

The Goh Cheng Liang Proton Therapy Centre at NCCS will be equipped with the state-of-the-art PROBEAT treatment delivery system from Hitachi. The setup will include four treatment gantries capable of 360° rotation and a fixed-beam room.

Hitachi's treatment delivery system includes dose driven continuous scanning (DDCS) functionality – an innovative technique aimed at improving proton dose delivery accuracy. RayStation is currently the only treatment planning system to support DDCS.

In addition to manual planning licences for pencil beam scanning, the RayStation installation will also include machine learning capabilities for both segmentation and automatic planning.

Johan Löf, founder and CEO, RaySearch, says: "We are proud to be part of NCCS's new and advanced proton therapy investment, which will benefit patients in Singapore. Techniques such as DDCS are pushing the frontiers of radiation therapy, and it is a priority for us to incorporate the latest developments. We are committed to ensuring that RayStation is the most compatible treatment planning system, leading the way in supporting the latest clinical advances."

The total order value is about 2.7 MEUR, including a five-year service contract.

About RaySearch

RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation® and next-generation oncology information system RayCare®*. The latest additions to RaySearch's product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analysis system (OAS) that cancer clinics can use to collect, structure and analyze data. The treatment control system (TCS) RayCommand® is designed as a link between the treatment machine and the systems for dose planning and oncology information. RaySearch software is used in about 2,600 clinics in over 65 countries. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation

RayStation® is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

More information about RaySearch is available at raysearchlabs.com

For further information, please contact:

Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)8-510 530 00

johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)70 661 05 59

peter.thysell@raysearchlabs.com

** Subject to regulatory clearance in some markets.*